Clinical Trials Logo

Hypoalbuminemia clinical trials

View clinical trials related to Hypoalbuminemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04071041 Terminated - Clinical trials for Community-acquired Pneumonia

Effect of Albumin Administration in Hypoalbuminemic Hospitalized Patients With Community-acquired Pneumonia.

ALBUCAP
Start date: October 31, 2019
Phase: Phase 3
Study type: Interventional

Community-acquired pneumonia (CAP) remains a leading cause of death world-wide. Hypoalbuminemia is associated with worse outcomes. However, whether albumin administration would have a beneficial effect in outcome in patients with CAP remains uncertain. This project proposes to test the hypothesis of whether the administration of albumin in hypoalbuminemic patients with CAP would increase the proportion of clinical stable patients at day 5.

NCT ID: NCT02755155 Terminated - Shock Clinical Trials

Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients

AlbAlsace
Start date: September 2016
Phase: Phase 4
Study type: Interventional

Primary purpose : mortality at Day 28 Secondary purposes : - Daily SOFA (Sequential Organ Failure Assessment) score lessening within Intensive Care Unit (ICU) - Duration of increasing doses of norepinephrine infusion to maintain target mean arterial pressure - Number of care-related infections within ICU

NCT ID: NCT02457702 Terminated - Clinical trials for Hepatic Insufficiency

Mitochondrial Function in Patients With Severe Liver Disease

SLDglyc
Start date: October 2015
Phase: N/A
Study type: Interventional

The researchers will recruit patients with liver disease at Parkland Hospital. Patients will fast overnight, and the next morning will receive an oral mixture of [U-13C3]glycerol (25 mg/kg) plus unlabeled glycerol (25 mg/kg). The total dose of glycerol will be 50 mg/kg in 100 milliliters of water. The taste is slightly sweet. Blood will be drawn at 60 min and 120 min after the ingestion. Blood glucose will be isolated and analyzed by NMR. The presence of [5,6-13C2]- and [4,5-13C2]glucose indicates preserved mitochondrial function. The researchers anticipate that patients with severe liver disease will show a decrease in mitochondrial function and will inform biosynthetic function of liver mitochondria. After the first 6 successful exams (see power analysis, below), healthy volunteers (age-, gender-, and race-matched) will be studied at the AIRC and subject to the same protocol.

NCT ID: NCT00529633 Terminated - Hypoalbuminemia Clinical Trials

The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients

ICM
Start date: September 2007
Phase: Phase 3
Study type: Interventional

Both malnutrition and inflammation are associated with death in dialysis patients and also with cardiovascular disease. The researchers are testing the idea that inflammation causes malnutrition by using a drug to suppress inflammation in hemodialysis patients to find out whether that will increase blood tests that are associated with malnutrition. The researchers will give hemodialysis patients who have both inflammation and malnutrition either thalidomide or a placebo and compare the effects of treatment on the levels of two proteins in the blood, albumin and prealbumin, that are normally reduced in malnourished patients. Patients who have a serum albumin concentration < 3.8 g/dl will be asked to sign consent to have blood drawn prior to dialysis for measurement of CRP (C-reactive protein). Those with CRP values ≥ 0.8 mg/dl will have a second measurement of CRP performed within 2 weeks. Those with two consecutive values of CRP ≥ 0.8 mg/dl will be eligible for enrollment